• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Allergan stock in free fall


<



Once the price per share hits a low value such that the debt surpasses the market cap, then you got yourself the new Valeant! Saunders doesnt know what hes doing. Investment banks are pulling money out of AGN cause they see how Saunders has destroyed shareholder value.
 




















What a disaster BS has turned this company into.........
So glad i'm not there anymore.
It's actually really sad, I feel bad for the employees that are still there and suffering through.....
The board needs to get him out of there!!
Such slimy tactics
 




What a disaster BS has turned this company into.........
So glad i'm not there anymore.
It's actually really sad, I feel bad for the employees that are still there and suffering through.....
The board needs to get him out of there!!
Such slimy tactics


Im not a fan of Saunders but what choices did have? Save $1.4 billion in Restasis revenue or give it up to double jeopardy lawsuits? Time will tell, but this might have been one of the better moves he has made even under all the criticism.